Who
Andrew Hirsch
Director
Company insider
Files Form 4 as: Director, Editas Medicine; President & CEO, C4 Therapeutics; Chief Financial Officer, Agios Pharmaceuticals; President & CEO, BIND Therapeutics.
In numbers
- Trades disclosed
- 80
- Buys
- 1
- Sells
- 0
- Bought
- $84K
- Sold
- $0
- Companies
- 4
- Companies where not an officer
- 1
- First trade
- 11 Mar 2014
- Last trade
- 17 Jun 2026
- Last filed
- 22 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —51,700 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,400 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K9,057 at $1.89 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —20,400 at $0.00 | filing |
| 15 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $17K9,057 at $1.89 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —81,725 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $74K39,154 at $1.89 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —81,725 at $0.00 | filing |
| 14 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $74K39,154 at $1.89 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 13 Feb 2026filed 18 Feb 2026 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —700,000 at $0.00 | filing |
| 6 Jun 2025filed 10 Jun 2025 | EDIT Editas Medicineoption or derivative · Genomics & Gene Editing | SEC FORM 4 Code A | —37,500 at $0.00 | filing |
| 15 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $30K9,370 at $3.18 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —335,300 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code A | —223,500 at $0.00 | filing |
| 14 Feb 2025filed 18 Feb 2025 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $41K12,847 at $3.18 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code M | —12,500 | filing |
| 7 Nov 2024filed 12 Nov 2024 | CCCC C4 TherapeuticsBiotechnology | SEC FORM 4 Code F | $34K5,550 at $6.04 | filing |
News
Head-To-Head Comparison: ACADIA Pharmaceuticals (NASDAQ:ACAD) versus C4 Therapeutics (NASDAQ:CCCC)CCCC · tickerreport.com · 19 Oct 2026Critical Review: ACADIA Pharmaceuticals (NASDAQ:ACAD) and C4 Therapeutics (NASDAQ:CCCC)CCCC · dailypolitical.com · 15 Oct 2026
0 headlines in the last 90 days name Andrew Hirsch; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.